Literature DB >> 25962622

Treatment of headache following triptan failure after successful triptan therapy.

Marc E P Lenaerts1, James R Couch.   

Abstract

OPINION STATEMENT: Triptans should remain the first choice in migraine abortive treatment. They are not always effective or adequate for specific patients. Before declaring a triptan in appropriate for a given patient, the provider ought to be analytical about the rationale and especially the use of objective efficacy outcome measures and ensure that treatment is prescribed and used appropriately. Other ergot derivatives, especially dihydroergotamine, may on one hand share common contraindications of triptans but on the other hand can be quite effective where triptans failed. Non-steroids are simple, readily available, and overall safe, and evidence for their efficacy in migraine is plentiful. Opioid analgesics are blatantly overprescribed especially in non-complicated migraine patients. These should be used with great care and restraint and closely monitored. Frequent opioid usage often leads to tolerance, dependence, and medication overuse headache. Neurostimulation is gaining momentum in the armamentarium of migraine management but at the present time remains primarily focused on prophylaxis, yet abortive use is expected to grow.

Entities:  

Year:  2015        PMID: 25962622     DOI: 10.1007/s11940-015-0353-6

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  32 in total

1.  Can vagus nerve stimulation help migraine?

Authors:  M E Lenaerts; K J Oommen; J R Couch; V Skaggs
Journal:  Cephalalgia       Date:  2008-02-14       Impact factor: 6.292

2.  The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin-norepinephrine reuptake inhibitors: American Headache Society position paper.

Authors:  Randolph W Evans; Stewart J Tepper; Robert E Shapiro; Christina Sun-Edelstein; Gretchen E Tietjen
Journal:  Headache       Date:  2010-06       Impact factor: 5.887

3.  Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache.

Authors:  K R Edwards; J Norton; M Behnke
Journal:  Headache       Date:  2001 Nov-Dec       Impact factor: 5.887

Review 4.  Pharmacological synergy: the next frontier on therapeutic advancement for migraine.

Authors:  Andrew Blumenfeld; Chris Gennings; Roger Cady
Journal:  Headache       Date:  2012-01-06       Impact factor: 5.887

5.  Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.

Authors: 
Journal:  Cephalalgia       Date:  1999-05       Impact factor: 6.292

6.  A sumatriptan iontophoretic transdermal system for the acute treatment of migraine.

Authors:  Jerome Goldstein; Timothy R Smith; Neil Pugach; Jim Griesser; Terri Sebree; Mark Pierce
Journal:  Headache       Date:  2012-06-13       Impact factor: 5.887

7.  Repetitive intravenous dihydroergotamine as therapy for intractable migraine.

Authors:  N H Raskin
Journal:  Neurology       Date:  1986-07       Impact factor: 9.910

8.  Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine.

Authors:  C Y Loo; H J Tan; H S Teh; A A Raymond
Journal:  Singapore Med J       Date:  2007-09       Impact factor: 1.858

9.  Home administration of intramuscular DHE for the treatment of acute migraine headache.

Authors:  M A Weisz; M el-Raheb; H J Blumenthal
Journal:  Headache       Date:  1994-06       Impact factor: 5.887

10.  Safety and patients' satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: a survey of 2,313 headache sufferers in the general population.

Authors:  Delphine Magis; Simona Sava; Tullia Sasso d'Elia; Roberta Baschi; Jean Schoenen
Journal:  J Headache Pain       Date:  2013-12-01       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.